Brief: Actinium Presents Interim Data From Actimab-A Clag-M Phase 1 Combination Trial At The 62nd American Society Of Hematology Annual Meeting
07/12/2020 12:03
Dec 7 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PRESENTS INTERIM DATA FROM ACTIMAB-A CLAG-M PHASE
1
COMBINATION TRIAL AT THE 62ND AMERICAN SOCIETY OF HEMATOLOGY
ANNUAL MEETING
* ACTINIUM PHARMACEUTICALS INC - 100% REMISSION RATE IN
THIRD DOSE
COHORT OF 0.75 ΜCI/KG OF ACTIMAB-A (LINTUZUMAB-225AC) AND
STANDARD REGIMEN OF CLAG-M
* ACTINIUM PHARMACEUTICALS INC - 70% OF PATIENTS ACHIEVING
REMISSION WERE MRD NEGATIVE WITH REMISSIONS AND MRD NEGATIVITY
REPORTED IN ALL DOSE COHORTS
Source text for Eikon: ID:nPn2qRJ1ka
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities